Alesi funding news – UK-based Alesi Secures £5Million in a Funding

The Cardiff University spin-out has developed a cutting-edge device to control smoke produced by surgical instruments in operating rooms. The dangers of smoke produced by electronic surgical instruments are becoming more well acknowledged. During keyhole surgery, smoke obstructs vision and causes fogging of the cameras, which disrupts workflow. Because human tissue contains poisons and viruses, it also puts theater employees' health at danger.

Eighteen US states have already approved legislation mandating a smoke management strategy for all surgical procedures, and more are anticipated. Nonetheless, surgeons dislike the clumsiness, noise, and unpopularity of the present methods, which include extraction tubes that need to be fastened to surgical equipment.

Alesi's technique extracts surgical smoke from the air by electrical filtration. With almost 40,000 procedures performed, the first-generation Ultravision system was created for laparoscopic surgery.

Read also - Battolyser Systems funding news – Dutch-based Battolyser Systems Secures €30Million in Series A Round Funding

Independent studies have demonstrated that it catches and lowers the infectivity of viruses in the smoke, and that it is 23 times more effective than alternative treatments at minimizing smoke release during laparoscopies.

The most recent version, Ultravision2, is a platform technology that can be integrated into surgical instruments and pre-existing theater equipment. It has received FDA approval. The initial integrated instrument designed for laparoscopic procedures,

The IonPencil now offers smoke control options for all surgical procedures that produce smoke thanks to the FDA's approval of the device for normal surgery. Each year, more than 40 million of these procedures are carried out in the USA, Europe, and Japan.

Dominic Griffiths, CEO of Alesi Surgical, commented: “We have been overwhelmed with the positive feedback we received from surgeons during the development of the IonPencil. As they have been reluctant to adopt the current systems, we believe our device will greatly improve compliance with new legislation. We are also pleased to welcome Mercia Ventures as a new investor alongside our existing investors and are eager to put this latest capital to good use to fuel our future growth.”

Robert Hornby, Investor Director at Mercia Ventures, added: “Introducing new regulations will drive uptake of smoke management solutions in the years ahead. Alesi’s technology offers many advantages over current systems. The company has already established a name for itself with its laparoscopy systems, but the IonPencil will open up a much wider market. We look forward to supporting Dominic and the team in this new chapter in the company’s growth.”

Alesi will be able to increase US sales and pursue regulatory approvals for its goods in Europe and Japan with the help of the most recent investment.

About Alesi

Alesi Surgical declared in 2023 that the FDA had approved its ground-breaking Ultravision2 smoke control system. The revolutionary new Ultravision system comes with the first surgical tool in the world that combines the best surgical smoke control and electrosurgery into a single laparoscopic instrument.